NYMX News and Press, Nymox Pharmaceutical Corporation From 07/14/21

Shares of Nymox Pharmaceutical Corporation (NASDAQ:NYMX) traded at a new 52-week low today of $1.38. Approximately 132,000 shares have changed hands today, as compared to an average 30-day volume of 576,000 shares. Nymox Pharmaceutical Corp is a biopharmaceutical company. The firm and it...

Nymox Pharmaceutical ([[NYMX]] -4.0%) proposes the resale of up to 3.7M shares by certain selling security holders.The proposal includes 1.8M share purchase warrants, issued to Alliance Global Partners or their assigned entities.The company highlighted that it will not receive any o...

Microcap biotech Nymox Pharmaceutical ([[NYMX]] -2.1%) expects to file for marketing approval for Fexapotide Triflutate in benign prostatic hyperplasia (enlarged prostate) on or before September 15, 2021."The company will file on or before September 15. We hope but cannot be certain that...

HASBROUCK HEIGHTS, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce that it will be filing for marketing approval of Fexapotide Triflutate for BPH before the end of the summer, on or before 15 Septemb...

Gainers: Brooklyn ImmunoTherapeutics (BTX) +44%.Uxin (UXIN) +25%.Ashford Hospitality Trust (AHT) +24%.Boxlight (BOXL) +21%.ADMA Biologics (ADMA) +18%.Clover Health Investments (CLOV) +16%.Unitil (UTL) +15%.Pitney Bowes (PBI) +15%.ClearSign Technologies (CLIR) +15%.Microvision (MVIS) ...

Nymox Pharmaceutical (NYMX) trades 15.9% down premarket after entering into a definitive agreement with institutional investors in a private placement of 3.7M shares and warrants to purchase 1.83M shares at a combined purchase price of $2.18/share for gross proceeds of ~$8M.The...

HASBROUCK HEIGHTS, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) today announced it has entered into a definitive agreement with institutional investors in a private placement of 3,669,724 shares of common stock and wa...

Nymox Pharmaceutical (NYMX) plans on filing an NDA for its benign prostatic hyperplasia (BPH) injectable drug fexapotide this summer.The company previously said it would file in Q1 2021.Fexapotide has a new mechanism of action for a BPH drug and works by inducing apoptosis -- cell death ...

HASBROUCK HEIGHTS, N.J., March 29, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide the latest update on the Company's regulatory filing preparation activities. The Company expects to file for approval for its first in class BPH treatment Fexapo...

HASBROUCK HEIGHTS, N.J., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide a current update on the regulatory filing status for Fexapotide Triflutate (FT), Nymox's first in class lead product for the treatment of benign prostatic hyperpl...